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Abstract
Salvinorin A (SalA), a selective κ-opioid receptor (KOR) agonist, produces dysphoria and pro-
depressant like effects. These actions have been attributed to inhibition of striatal dopamine
release. The dopamine transporter (DAT) regulates dopamine transmission via uptake of released
neurotransmitter. KORs are apposed to DAT in dopamine nerve terminals suggesting an additional
target by which SalA modulates dopamine transmission. SalA produced a concentration-
dependent, nor-binaltorphimine (BNI)- and pertussis toxin-sensitive increase of ASP+
accumulation in EM4 cells coexpressing myc-KOR and YFP-DAT, using live cell imaging and
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the fluorescent monoamine transporter substrate, trans 4-(4-(dimethylamino)-styryl)-N-
methylpyridinium) (ASP+). Other KOR agonists also increased DAT activity that was abolished
by BNI pretreatment. While SalA increased DAT activity, SalA treatment decreased serotonin
transporter (SERT) activity and had no effect on norepinephrine transporter (NET) activity. In
striatum, SalA increased the Vmax for DAT mediated DA transport and DAT surface expression.
SalA up-regulation of DAT function is mediated by KOR activation and the KOR-linked
extracellular signal regulated kinase-½ (ERK1/2) pathway. Co-immunoprecipitation and BRET
studies revealed that DAT and KOR exist in a complex. In live cells, DAT and KOR exhibited
robust FRET signals under basal conditions. SalA exposure caused a rapid and significant increase
of the FRET signal. This suggests that the formation of KOR and DAT complexes is promoted in
response to KOR activation. Together, these data suggest that enhanced DA transport and
decreased DA release resulting in decreased dopamine signaling may contribute to the dysphoric
and pro-depressant like effects of SalA and other KOR agonists.
Keywords
kappa opioid receptor; dysphoric; pro-depressant; dopamine transporter; serotonin transporter;
trafficking; salvinorin A
1. Introduction
Salvinorin A (SalA) is a naturally occurring κ-opioid receptor (KOR) agonist that produces
psychotomimesis, dysphoria and prodepressant like effects (Vortherms and Roth, 2006).
Despite a surge in its recreational use (Griffin et al., 2008), the neural correlates mediating
these effects are unknown. Decreased dopamine signaling in the dorsal and ventral striatum
is implicated in the induction of dysphoria and the pathogenesis of depression (Mizrahi et
al., 2007). KOR agonists decrease dopamine concentrations in these regions; an effect
attributed to inhibition of dopamine release (Shippenberg et al., 2007; Spanagel et al., 1990).
The dopamine transporter (DAT) rapidly clears the dopamine released into the extracellular
space and the activity of DAT is the determinant of dopamine signaling (Amara and Kuhar,
1993). It is largely evident that DAT activity is rapidly altered in response to activation and
or inhibition of several protein kinases and protein phosphatase PP1/PP2Ac. For example,
activation of PKC as well as inhibition of ERK1/2, PI-3 kinase, CaMKII, Cdk5 and tyrosine
kinase rapidly decrease DA uptake (Carvelli et al., 2002; Doolen and Zahniser, 2001; Fog et
al., 2006; Moron et al., 2003; Price et al., 2009; Zhang et al., 1997). In addition, while
activation of D2, D3 DA receptors (D2sR, D3R), TrkB and insulin receptors stimulates DA
uptake, activation of NK1R or mGluR5 reduces DA uptake (Bolan et al., 2007; Garcia et al.,
2005; Granas et al., 2003; Hoover et al., 2007; Lee et al., 2007; Mayfield and Zahniser,
2001; Page et al., 2001; Zapata et al., 2007). Thus, G-protein coupled receptor (GPCR) and
non-GPCR receptor regulation of DAT has been well documented (reviewed and references
therein (Ramamoorthy et al., 2011)). The contributions of regulated DAT phosphorylation
(Khoshbouei et al., 2004), ubiquitylation (Miranda et al., 2005), palmitoylation (Foster and
Vaughan, 2011), glycosylation (Li et al., 2004), protein-protein interaction (reviewed
(Eriksen et al., 2010)-therein references) and lipid-raft distribution (Adkins et al., 2007)
have been demonstrated in regulating DAT-trafficking, DAT-mediated DA-efflux and
Kivell et al. Page 2






















degradation. Furthermore, DAT-substrates and inhibitors can also influence kinase/
phosphatase mediated DAT regulation (Melikian, 2004; Pramod et al., 2013; Ramamoorthy
et al., 2011; Vaughan and Foster, 2013).
KOR is apposed to DAT in striatal dopamine axons and varicosities (Svingos et al., 2001).
These findings indicate that KOR is strategically located to regulate dopamine uptake and
that DAT may be a target upon which SalA acts to modulate dopamine transmission and
behavior. However, our knowledge of the SalA mediated KOR-signaling mechanisms that
contribute to DAT regulation is incomplete. The present studies, conducted in heterologous
expression systems and native tissue, examined whether SalA modulates DAT function and
the intracellular mechanisms mediating this effect.
2. Materials and Methods
2.1. Live Cell Imaging to Quantify DAT function
Experiments were conducted in HEK-293 (HEK) and EM4 cells, a HEK cell line expressing
a macrophage scavenger receptor to increase adherence to tissue culture plastic. Cells were
maintained in DMEM/Ham's F-12 medium (50:50; Mediatech Inc., Herndon, VA)
supplemented with 10% FBS and grown in a humidified atmosphere (37°C and 5% CO2).
Cells were transfected with myc-rat KOR (KOR; 0.1 μg) and either 0.3 μg of YFP-human
DAT (DAT), eGFP-rat DAT (rDAT), FLAG-human DAT (FLAG-DAT) or GFP-human
norepinephrine transporter (NET), or human serotonin transporter (hSERT) 24 h after
plating, using Lipofectamine™ LTX (Invitrogen, Carlsbad, CA). Experiments were
performed 48 h later (cell confluency: 70-80%). Addition of these tags does not alter the
trafficking, protein localization or function (Jordan and Devi, 1999; Zapata et al., 2007).
Time-resolved quantification of DAT function in single cells was achieved using the
fluorescent, high affinity monoamine transporter substrate 4-(4-diethylaminostyryl)-N-
methylpyridinium iodide (ASP+) (Schwartz et al., 2003). ASP+ is a sensitive probe for
monitoring monoamine transporter function (Bolan et al., 2007; Schwartz et al., 2003;
Zapata et al., 2007). ASP+ accumulation is linear for 10 min after ASP+ addition, inhibited
by substrates and dependent on temperature and extracellular NaCl concentrations.
Immediately before experiments, media was removed and cells washed in Krebs-Ringer/
HEPES medium (KRH in mM: 130 NaCl, 1.3 KCl, 2.2 CaCl2, 1.2 MgS04, 1.2 KH2PO4, 10
HEPES, and 1.8 g/liter glucose, pH 7.4). Fresh KRH was added, and the culture dish was
mounted on an Ultra VIEW™ LCI spinning-disk (PerkinElmer Life Sciences (Grand Island,
NY) or Olympus FV1000 (Olympus, Tokyo, Japan) confocal microscope (60x water
objective lens). A within cell design was used to assess the effects of graded SalA
concentrations (0.1-10 μM), and to determine ASP+ uptake kinetics. The microscope was
focused on a cell monolayer and background auto-fluorescence determined by collecting an
image immediately prior to replacing buffer with that containing ASP+ (10 μM). SalA, SalA,
U69,593 or U50,488 or vehicle was added 5 min later. The slope of ASP+ accumulation was
determined before and after addition. Images were collected every 20 s for 10 min to capture
YFP or GFP (excitation, 488 nm; emission, 525–575 nm) and ASP+ fluorescence
(excitation, 488 nm; emission, 607–652 nm). To determine ASP+ uptake kinetics, a range of
ASP+ concentrations (0-16 μM) were used. The slope of uptake phase was determined
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following background subtraction (cells not expressing DAT) and normalization to cell
surface expression of either DAT or SERT. For studies assessing the effects of the selective
KOR antagonist, nor-binaltorphimine (BNI: 1 μM; 10 min), pertussis toxin (PTX: 100
ng/ml; 16-24 hr) or the selective extracellular signal regulated kinase 1/2 (ERK) inhibitor,
PD98059 (10 μM; 15 min) or p38 MAP kinase inhibitor SB203580 (3 μM; 5 min) (Tocris;
Minneapolis, MN) or dopamine D2 receptor antagonist L-741,626 (10 μM; 5 min) (Tocris;
Minneapolis, MN) on SalA-evoked alterations of ASP+ uptake, cells were incubated with
drug for the indicated times and the slope of ASP+ accumulation quantified as above. Drug
concentrations were chosen based on reported effective concentrations (Alessi et al., 1995;
Bolan et al., 2007; Dalman and O'Malley, 1999; Grilli et al., 2009; Zapata et al., 2007).
Fluorescent images were processed using Velocity (PerkinElmer Life Sciences) and NIH
ImageJ (version 1.32) software. Within cell fluorescent accumulation, defined by GFP or
YFP plasma membrane fluorescence, was measured as average pixel intensity of time-
resolved images. Data are expressed as arbitrary fluorescence units (AFU) or percent change
in ASP+ uptake rate after drug addition. Typically 30–100 cells from three separate
transfections were used.
2.2. Quantification of Striatal DAT Function
All Procedures with rodents were approved by the Institutional Animal Care and Use
Committee in accordance with the National Institutes of Health Guide (NIH Publication No.
8023, revised 1978) for the Care and Use of Laboratory Animals and the Victoria University
of Wellington Animal Ethics Committee. Rats were maintained in a temperature and
humidity controlled room on a 12:12 h light/dark cycle. Food and water were supplied ad
libitum. All efforts and care were taken to minimize animal suffering and to reduce the
number of animals used. As alternatives to brain tissues, cell culture models were utilized.
2.2.1. Rotating Disk Electrode (RDE) Voltammetry—RDE was used to determine the
initial velocity of dopamine clearance in minces of the striatal tissue of rats as previously
described using an electrode rotation rate of 4000 rpm and an applied potential of +450 mV
versus Ag/AgCl reference electrode (Thompson et al., 2000). Voltage output was monitored
until stable baselines were obtained (≅10 min). SalA or U50,488 (3 μl; final cell
concentration: 10 nM) or an equivalent volume of vehicle was added to the electrochemical
cell 4-5 min prior to addition of dopamine (6 μl; final concentration: 2 μM). PD98050 (3 μl;
final concentration: 10 μM) was added to the cell, followed 10 min later by SalA. The
resultant signals were detected as changes in voltage output versus time using
electrochemical detection. The initial rate of signal decay after dopamine addition was
calculated for 10 s. Rates of nonspecific signal decay, defined as signal decay in the absence
of tissue at the end of each experimental day, were subtracted from that in the presence of
tissue to calculate initial velocity of DA clearance (pmoles/s/g wet weight tissue). DA-
clearance in the presence of GBR12909 was subtracted from DA clearance in absence of
GBR12909 to derive DAT-mediated DA clearance..
2.2.2. [3H]DA uptake assay—Synaptosomes from striatum were prepared and [3H]DA
uptake was measured as described previously (Tejeda et al., 2013). Briefly, rats were rapidly
decapitated, and striatal regions were dissected and collected in 10 volumes (wt/vol) of cold
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0.32 M sucrose. The tissue was immediately homogenized using a Teflon-glass
homogenizer and centrifuged at 1000 × g for 15 min at 4°C. The resulting supernatant was
centrifuged at 12,000 × g for 20 min and the pellet was washed by resuspending in 0.32 M
sucrose. The synaptosomal preparation was used immediately for experiments. Protein
concentration was determined by DC protein assay (BioRad) using bovine serum albumin as
standard. Striatal synaptosomes (40 μg) were incubated in a total volume of 0.5 ml of Krebs-
Ringer-HEPES (KRH) buffer consisting of 120 mM NaCl, 4.7 mM KCl, 2.2 mM CaCl2 10
mM HEPES, 1.2 mM MgSO4, 1.2 mM KH2PO4, 5 mM Tris, 10 mM D- glucose, pH 7.4
containing 0.1 mM ascorbic acid, and 0.1 mM pargyline in the presence of SalA (10 μM) or
appropriate vehicle at 37°C for 5 min. Uptake was initiated by the addition of 10 nM
[3H]DA (78 Ci/mmoldihydroxyphenylethylamine [2,5,6,7,8-3H], PerkinElmer, Santa Clara,
CA). Unlabelled DA was used along with [3H]DA from 0.01 nM to 2.0 μM for saturation
analysis. Uptake was terminated with the addition of 3 ml ice-cold PBS followed by rapid
filtration over 0.3% polyethylenimine coated GF-B filters on a Brandel Cell Harvester
(Brandel Inc., Gaithersburg, MD). Filters were washed rapidly with 5 ml cold PBS and
radioactivity bound to filter was counted by liquid scintillation counter. Nonspecific uptake,
defined as the uptake in the presence of 100 μM cocaine, was subtracted from total
accumulation of [3H]DA to yield specific total DA uptake (representing DA uptake
mediated by both DAT and NET). To isolate only DAT-mediated [3H]DA uptake from total
[3H]DA uptake (DAT/NET-specific), NET-specific blocker nisoxetine (50 nM) was used to
block NET-mediated DA transport as described earlier (Tejeda et al., 2013). DAT specific
DA uptake was further verified using specific DAT blocker GBR12909 (50 nM) or
nomifensine (100 nM). DAT activity isolated in this manner was completely blocked by
DAT blockers GB12909 or nomifensine. Thus, [3H]DA uptake in the presence of nisoxetine
corresponds to specific DA uptake through DAT. All uptake assays were performed in
triplicates and expressed as mean values of specific uptake ± S.E.M.
2.3. Immunoblotting of ERK1/2 and p38 MAPK
Immunoblotting of phosphorylated ERK (p-ERK) and p38 MAPK (phospho-p38 MAPK)
were conducted in EM4 cells that are serum-starved for 2 h. Cells were incubated with SalA
(10 μM) or vehicle for 5 min at 37 °C. PD98059 (10 μM) was preincubated for 15 min prior
to SalA addition. Following the treatment, the media was aspirated and the cells were
washed before solubilizing with RIPA buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1
mM EDTA, 1% Triton X-100, 0.1% SDS, and 1% sodium deoxycholate) supplemented with
a cocktail of protease and phosphatase inhibitors. Equal amount of protein was incubated
with Laemmli buffer (62.5 mM Tris, pH 6.8, 20% glycerol, 2% SDS, 5% β-
mercaptoethanol, and 0.01% bromphenol blue) and proteins separated by SDS-PAGE and
transferred onto polyvinylidene difluoride membranes (Millipore, Bellerica, MA).
Membranes were blocked for 1 h at room temperature in TBS-T containing 5% nonfat milk.
p-ERK and phospho-p38 MAPK were detected using rabbit polyclonal antibody specific for
p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 and threonine 180 and
tyrosine 182 respectively. To analyze total ERK and p38 MAPK levels, blots were stripped
with 2% SDS and 100 mM β-mercaptoethanol in 62.5 mM Tris, pH 6.8, for 1 h at 50 °C and
reprobed with polyclonal antibodies (Cell Signaling Technology, Inc. Beverly, MA)
recognizing total ERK or total p38 MAPK. Blots were visualized using HRP-conjugated
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secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) with
enhanced chemiluminescence reagents (Amersham Biosciences, GE healthcare, NJ).
Multiple exposures were evaluated by digital quantitation using NIH ImageJ (version 1.32j)
software to ensure that results were within the linear range of film exposure. Amounts of p-
ERK and phospho-p38 MAPK were normalized to that of total ERK and total p38 MAPK
respectively (Bolan et al., 2007).
2.4. Cell Surface Biotinylation and Immunoblotting
Cell surface biotinylation and immunoblotting was performed as described previously
(Zapata et al., 2007). Cells: Briefly, EM4 cells (100,000 cells/well) transfected with myc-
KOR and FLAG-DAT were grown in 12 well plates were first washed PBS/Ca-Mg (138
mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 9.6 mM Na2HPO4, 1 mM MgCl2, 0.1 mM
CaCl2, pH 7.3). Where indicated, cells were treated with different modulators at 37°C as
described in figure legends. Then cells were incubated with EZ link NHS-Sulfo-SS-biotin (1
mg/ml) (Thermo Fisher Scientific, Rockford, IL) in cold PBS/Ca-Mg for 30 min on ice and
then the excess biotinylating reagents were removed by two times wash with 100 mM
glycine and further incubated with glycine for 20 min. The cells were solubilized using
RIPA buffer supplemented with a cocktail of protease inhibitors. Synaptosomes: Briefly,
Synaptosomes (300 to 500 μg) were incubated in Krebs-Ringer buffer with indicated
modulators or vehicle at 37°C for the times indicated in figure legends (Samuvel et al.,
2008). The samples were washed quickly by centrifugation, and the pellets were treated with
EZ link NHS-Sulfo-SS-biotin (1 mg/1 mg protein) for 30 min at 4°C in in cold Krebs-
bicarbonate buffer. Subsequently, the samples were washed with the same buffer containing
100 mM glycine, and the pellet was resuspended in RIPA lysis buffer. The resuspended
synaptosomes or solubilized cells were triturated 10 times through a 25 gauge needle and
centrifuged at 25,000 × g for 30 min. Total cellular protein content was determined by the
Bradford Protein Assay procedure. Using equal amounts of solubilized proteins, the
biotinylated proteins were isolated using NeutrAvidin Agarose resins overnight at 4°C
followed by washing. Bound proteins were eluted with 50 μl Laemmli sample buffer for 30
min at room temperature. Aliquots from total extracts, unbound fractions and all of the
eluate were separated by SDS-PAGE, transferred to polyvinylidene difluoride membrane
and probed with DAT specific (Santa Cruz Biotechnology, Inc. Dallas, TX) or other
antibodies as indicated. The immunoreactive proteins were visualized using ECL or ECL
plus reagent. Subsequently, the blots were stripped and reprobed with anti-calnexin antibody
(AKELA Pharma Inc. Montreal, QC, Canada) to validate the surface biotinylation of plasma
membrane proteins as well as protein loading levels. DAT densities from total and
biotinylated (representing the surface pool) fractions were normalized using levels of
calnexin in the total extract. Multiple exposures were evaluated by digital quantitation using
NIH ImageJ (version 1.32j) software to ensure that results were within the linear range of
the film exposure (Samuvel et al., 2008; Zapata et al., 2007).
2.5. Identification of DAT-KOR Complexes
2.5.1. Co-immunoprecipitation and Immunoblot Analysis—Co-
immunoprecipitation experiments were conducted using EM4 cells or striatal synaptosomes.
A. EM4 cells: Co-immunoprecipitation experiments were conducted as previously described
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(Bolan et al., 2007) in EM4 cells expressing myc-KOR and FLAG-DAT alone or together.
Protein samples were prepared by incubation of cells with RIPA buffer pH 7.4, for 30 min
(4°C) followed by centrifugation (25,000 × g for 30 min). Complexes were
immunoprecipitated with polyclonal anti-myc antibodies (rabbit, clone A-14, Santa Cruz
Biotechnology, CA). After pull down with Protein A-linked agarose beads, they were
washed three times with RIPA buffer and eluted at room temperature. Immunoprecipitates
were separated by SDS-PAGE (4-20% Duramide gradient gel, Cambrex, Walkersville, MD)
and blotted onto polyvinylidene difluoride membranes. DAT was detected using a
monoclonal antibody raised against the N-terminal domain of human DAT (Chemicon,
Temecula, CA) and secondary goat HRP-conjugated anti-rat antibody (Jackson
ImmunoResearch, West Grove, PA). B. Striatal synaptosomes. Presence of KOR protein in
immunoprecipitated DAT protein complex. Immunoprecipitation of DAT protein was
carried out using two DAT antibodies from Chemicon (Millipore), Billerica, MA and Santa
Cruz Biotechnology, Inc. Dellas, TX as described (Chakrabarti et al., 2010). Synaptosomes
(500-700 μg) were solubilized with 20 mM Hepes buffer, pH 7.4 containing 150 mM NaCl,
5 mM EDTA, 1% Triton X-100, 0.1% SDS supplemented with a cocktail of protease and
phosphatase inhibitors. In parallel, irrelevant IgG was used as a control. Clear solubilized
extract after centrifugation (25,000 g for 45 min) was incubated with DAT antibodies (4 μg)
overnight at 4°C, and the immunocomplex was isolated using Protein A and G Sepharose.
Immunoprecipitates eluted with Laemmli buffer with out β-mercaptoethanol. The eluted
samples were then incubated with 5% β-mercaptoethanol, and 0.01% bromphenol blue for
30 min at 22°C, electrophoresed as given above. The presence of KOR protein from DAT-
immunocomplex was detected by immunoblotting using rabbit polyclonal KOR-1 antibody
(Santa Cruz Biotechnology, Inc. Dellas, TX).
2.5.2. Biolumiescence Resonance Energy Transfer (BRET)—BRET studies were
carried out with HEK cells transfected with luciferase tagged KOR (Luc-KOR) alone or
with YFP-DAT as described previously using a FluoroMax-2 spectrometer and the Fusion
Microplate Reader (Bolan et al., 2007). BRET ratios were calculated as described by Angers
et al., (2000) (Angers et al., 2000). Cells transfected with Luc-KOR in combination with
YFP-tagged delta opioid receptor (YFP-DOR) were used as a positive control since studies
have shown that KOR and DOR functionally interact and are in close proximity (Gomes et
al., 2003). As a negative control, we used cells co-transfected with YFP-tagged chemokine
receptors CCR5 (YFP-CCR5) and Luc-KOR.
2.5.3. Fluorescence Resonance Energy Transfer (FRET)—FRET (Schmid and
Sitte, 2003) was measured with a Carl Zeiss Axiovert 200 epifluorescence microscope. The
‘three-filter method’ was performed as described in (Bartholomaus et al., 2008). Images
were taken using 63x oil immersion objectives and LUDL filter wheels allowing a rapid
excitation and emission filter exchange. We used HEK293 cells which were maintained and
transiently transfected with plasmid cDNA (1.7 μg) by means of the calcium phosphate co-
precipitation method as described previously (Sucic et al., 2010). The LUDL filter wheels
were configured as follows: CFP (IDonor; excitation: 436nm, emission: 480nm, and dichroic
mirror: 455nm), YFP (IAcceptor; excitation: 500nm, emission: 535nm, and dichroic mirror:
515nm) and FRET (IFRET; excitation: 436nm, emission: 535nm, and dichroic mirror:
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455nm). Images were taken with a CCD camera (Coolsnap fx, Roper Scientific).
Background fluorescence was subtracted from all images. We analyzed the images pixel by
pixel using ImageJ (Wayne Rassband, National Institute of Health, version 1.43b) and the
ImageJ plug-in PixFRET (Pixel by Pixel analysis of FRET with ImageJ, version 1.5.0; Feige
et al., 2003) with which spectral bleed-through (SBT) parameters for the donor bleed
through (BT) and the acceptor BT were determined and NFRET was calculated in the
following way:
The mean NFRET was measured at the plasma membrane (pre-defined as the region of
interest) using the computed NFRET-image. The regions of interest were selected in the CFP
(Donor) or YFP (Acceptor) image (to avoid bleaching-associated bias) and transmitted to
the NFRET-image by the ImageJ Multi Measure Tool. As negative control we employed the
YFP-labeled form of KOR with a membrane-bound form of CFP (kindly provided by R.Y.
Tsien). As positive controls for membrane proteins we used the SERT tagged with CFP and
YFP on its cytoplasmic N- and C-termini, respectively (to yield C-SERT-Y; (Just et al.,
2004)). We tagged DAT and GAT1 with CFP to reveal C-DAT and C-GAT1 (Schmid et al.,
2001) to compare the FRET values between Y-KOR and C-DAT or C-GAT1. To compare
expression levels of CFP- or YFP-tagged proteins, the fluorescence intensity within a rim of
a few pixels positioned over the membrane was measured and expressed in arbitrary
fluorescence units (a.f.u.).
2.6. Purification of SalA
SalA was isolated and purified from commercially available Salvia divinorum leaves as
described previously (Butelman et al., 2007; Tidgewell et al., 2004) and determined to be
>98% pure by HPLC.
2.7. Statistical Analysis
Values are expressed as mean ± S.E.M. As noted in the figure legends and in the result
section, one-way analysis of variance was used followed by post hoc testing (Bonferroni,
Dunnett and Tukey) for multiple comparisons. Two-tailed unpaired Student's t test analysis
was performed for comparisons between two groups using Prism (GraphPad, San Diego,
CA). A value of p ≤ 0.05 was considered statistically significant.
3. Results
3.1. KOR Activation upregulates DAT
3.1.1. SalA Increases DAT Function via KOR Activation—Addition of SalA to EM4
cells coexpressing KOR and DAT produced a concentration dependent increase in ASP+
accumulation rate (F (3, 211) =11.50; p ≤ 0.0001) (Fig. 1A). Increased accumulation occurred
within 2 min after ASP+ addition and persisted for at least 10 min. At 10 μM SalA, the
magnitude of stimulation of ASP+ accumulation rate varied between experiments with a
minimum of ∼20% to a maximum of ∼60%. ASP+ uptake as well as SalA-mediated
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increase in the ASP+ accumulation was also blocked by DAT inhibitor GBR 12909 (F (4,521)
=213; p < 0.0001) (Fig. 1B). GBR 12909 insensitive ASP+ accumulations found in cells
coexpressing DAT and KOR was similar to ASP+ accumulation in non-transfected cells
(Fig. 1B). SalA was found to be a highly potent and selective KOR agonist. In order to
validate whether SalA mediated stimulation of DAT activity was attributable to KOR, the
effect of SalA was assessed in the presence of a selective KOR antagonist, nor-
binaltorphimine (BNI). EM4 cells were preincubated for 10 min with BNI (1 μM) prior to
the addition of vehicle or SalA (10 μM) followed by measuring ASP+ accumulation and was
compared with vehicle treatment (Fig. 1D). While SalA increased DAT activity in the
absence of BNI, it did not alter DAT activity in the presence of BNI (F (3,212) =129; p ≤
0.0001). On the other hand, SalA increased ASP+ uptake both in the presence and absence
of D2 receptor antagonist, L-741,626 (Fig. 1C). Furthermore, SalA treatment of EM4 cells
expressing only the DAT did not produce any effect on DAT activity (Fig. 1C). These
results indicate that SalA induced stimulation of DAT is KOR mediated.
3.1.2. Other KOR Agonists Increase DAT Function Via KOR Activation—Next
we sought to examine whether SalA mediated DAT upregulation is unique to SalA or
general consequence of KOR activation. We tested the effect of other known KOR agonists
including U69,593 and U50,488 on DAT-mediated ASP+ accumulation in EM4 cells
coexpressing KOR and DAT. Similar to SalA, both U69,593 and U50,488 at 10 μM
increased ASP+ accumulation (F (3, 3175) =29.12; p ≤ 0.0001) (Fig. 1B). However,
preincubation of BNI (1 μM) for 10 min prior to the addition of vehicle or U69,593 or
U50,488 completely blocked the stimulatory effect on DAT activity (F (5,270) =18.73; p ≤
0.0001) (Fig. 1B), suggesting the involvement of KOR. Kinetic analysis of ASP+ uptake in
EM4 cells coexpressing the DAT and KOR proteins showed that SalA (10 μM) treatment
significantly increased the values of Vmax (vehicle: 1.09 ± 0.07 AFUs; SalA: 1.49 ± 0.89
AFUs; t= 3.24, df=741; p <0.001) and the values of Km (vehicle: 2.74 ± 0.55 μM; SalA:
5.31 ± 0.85 μM; t= 2.15, df=741; p <0.03). Thus, SalA increased the maximal velocity while
decreasing the affinity.
3.1.3. Differential Influence of SalA on Serotonin and Norepinephrine
Transporters—We next asked whether SalA regulates other amine transporters.
Treatment with SalA (10 μM, 10 min) significantly reduced SERT-mediated ASP+
accumulation in EM4 cells coexpressing KOR and human SERT (t=9.85, df=44 p<0.0001)
(Fig 1C). BNI pretreatment blocked the decrease in SERT activity induced by SalA (t=8.31,
df=26 p<0.0001) (Fig 1C). Kinetic analysis of ASP+ uptake by SERT revealed a significant
decrease in Vmax value (vehicle: 1.93 ± 0.47 AFUs; SalA: 0.86 ± 0.21 AFUs; t=2.08,
df=510 p<0.04) with no significant change in Km value following SalA treatment (vehicle:
9.46 ± 4.01 μM; SalA: 2.88 ± 2.89 μM; t= 1.34, df=519; p =0.18). On the other hand, SalA
(10 μM) and or BNI did not alter ASP+ accumulation in EM4 cells co-expressing KOR and
NET (p> 0.1) (Fig 1C). These results collectively indicate that SalA exhibits differential
effect on DAT and SERT while it has no influence on NET.
3.1.4. SalA-KOR Mediated DAT Upregulation is Dependent on Gi/Go and
ERK1/2 Activation—KOR is predominantly coupled to pertussis toxin (PTX) sensitive
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Gi/Go types of G proteins and triggers diverse signaling systems including ERK1/2
(Bruchas and Chavkin, 2010). Therefore, we examined whether SalA-KOR-mediated
stimulation of DAT activity requires Gi/Go and ERK1/2 activation. Pretreatment of EM4
cells coexpressing DAT and KOR with PTX (100 ng/ml for 16-24 hr) prevented SalA-
mediated increase in ASP+ uptake (Fig. 2A, F (3,268) =74.56, p = 0.0001). Next we examined
whether SalA treatment activates ERK1/2 and p38 MAPK in EM4 cells co-expressing DAT
and KOR by measuring ERK1/2 and p38 MAPK phosphorylation. Five min incubation of
EM4 cells with SalA (10 μM) produced a significant (t-test; p ≤ 0.0001; n=3) ∼2.5-fold
increase in pERK1/2 levels with out any changes in total ERK1/2 confirming ERK1/2
activation by SalA (Fig. 2B). Similar to SalA, 5 min exposure of U69,593 (10 μM, ∼ 3 fold,
t-test; p ≤ 0.005; n=3) or U50,488 (10 μM, ∼ 3.5 fold t-test; p ≤ 0.008; n=3) significantly
increased pERK1/2 levels (Fig. 2B) with out altering total ERK1/2 expression. However,
parallel analysis of the level of phospho-p38 MAPK and total p38 MAPK showed no
significant changes (F (5,30) = 1.67, p = 0.17) suggesting that KOR activation through SalA
or U69,593 or U50,488 activates ERK1/2, but not p38 MAPK under the experimental
conditions used. Incubation of cells with the ERK1/2 kinase inhibitor, PD98059 (10 μM),
did not alter ASP+ uptake but prevented SalA-evoked increases in ASP+ accumulation (Fig.
2C; F (3,278) = 42.23, p = 0.001). In contrast, pretreatment of cells with the p38 MAPK
inhibitor, SB203580 (3 μM; 5 min), was ineffective in attenuating SalA-evoked increases in
ASP+ accumulation rate (% increase in slope: Veh/SalA = 28.29 ± 2.9%; SB203580/SalA=
36.42 ± 6.6%; t=1.4; df =156, p > 0.15 n=39). Parallel analysis showed that, PD98059
specifically reduced the SalA induced pERK1/2 level with no effect on phospho- p38
MAPK or total ERK1/2 and or total p38 MAPK. These results are consistent with our
observations that SalA triggers ERK1/2 activation and subsequently upregulates DAT but
not p38 MAPK.
3.2. SalA Upregulates DA Clearance in Rat Striatum via ERK1/2
The above results (Figs. 1 & 2) revealed that SalA triggers DAT activity through KOR-
linked ERK1/2 activation in heterologous coexpressing cell model. Next we sought to
examine whether SalA upregulates DAT function in native tissue. Given the fact that KOR
is expressed in striatal dopamine axons and varicosities (Svingos et al., 2001), RDE
voltammetry and radiolabelled DA uptake was performed in mince preparations of striatal
tissue or synaptosomes respectively, to determine the effect of KOR activation on DAT
function. Analogous to our results using heterologous expression systems, SalA as well as
U50,488 significantly increased DAT mediated DA-transport in a GBR12909-sensitive
manner (Fig. 3A; F (2,30) = 7.03, p = 0.003) and was blocked by the presence of BNI (F (4,37)
= 7.06, p = 0.0003) suggesting specific KOR-mediated effect on DAT. Furthermore, the
ERK1/2 inhibitor PD98059 (10 μM) pretreatment (30 min) attenuated the SalA evoked DAT
function Fig. 3B. PD98059 at 10 μM concentration did not affect dopamine clearance
significantly (F (1,16) = 1.3; p = 0.3), but it attenuated the SalA-evoked increase in DA
clearance (F (1,16) = 5.1; p = 0.04).
3.3. SalA Increases DAT Vmax
The kinetic parameters of the DAT (Michaelis–Menten constant, Km, and maximal velocity,
Vmax) were determined in vehicle and SalA (10 μM; 5 min) treated striatal synaptosomes
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(Fig. 4). DAT-specific DA transport was determined in the presence of the NET blocker
nisoxetine (see details under methods and materials). SalA treatment increased the maximal
velocity (Vmax) significantly from 27.8 ± 4.4 to 45.10 ± 1.0 pmol/mg protein per minute (t=
3.84, df=4; p <0.009) with no significant changes in the Km (vehicle: 29.77 ± 1.24 nM;
SalA: 35.11 ± 2.23 nM; t= 2.09, df= 4; p=0.105)
3.4. SalA Upregulates DAT Cell Surface Expression
To determine whether up-regulation of DAT function is associated with increased DAT cell
surface expression, surface biotinylation studies were conducted in EM4 cells coexpressing
KOR and DAT (Fig. 5A). Consistent with the uptake data, SalA exposure of cells for 10 min
significantly increased biotinylated DAT (% of vehicle, 214.3 ± 18.31 %, p = 0.0001).
Treatment with SalA did not alter the total amount of DAT protein (Fig. 5A). Next, a rat
striatal synaptosome preparation was used for biotinylation studies to examine whether SalA
increases surface DAT in endogenously expressing preparations (Fig. 5B). Similar to the
cell model, and consistent with the change in Vmax of DA clearance, SalA exposure of
striatal synaptosomes resulted in a significant increase in surface DAT (% of vehicle, 183.7
± 13.2 %, p = 0.0001) without altering the total level of the DAT protein (Fig. 5B).
Furthermore, pretreatment of cells or striatal synaptosomes with the ERK1/2 inhibitor
PD98059 (10 μM, 30 min) blocked the SalA induced increase in surface DAT and
synaptosomes (in % of vehicle; cells: Veh/SalA: 214.3 ± 18.31%, PD98050/SalA: 122.6 ±
3.0 %, p=0.0007; synaptosomes: Veh/SalA: 183.7 ± 13.2%, PD98050/SalA: 97.5 ± 14.4%,
p=0.02). PD98059 at 10 μM concentration did not affect total and surface levels of DAT
(Fig. 5A & B). We validated our surface biotinylation experiments for cellular integrity by
determining the presence of intracellular calnexin in biotinylated fractions. Both in cells and
synaptosomal experiments, less than 0.5% of total calnexin was present in biotinylated
fractions suggesting that surface membranes were intact and intracellular proteins were not
significantly biotinylated and contaminated/recovered with surface biotinylated proteins
(data not shown).
3.5. DAT and KOR Interaction
3.5.1. DAT and KOR Exist in a Physical Complex—Our previous studies
demonstrated that DAT and presynaptic D2s-Receptor form a stable complex (Bolan et al.,
2007). Furthermore, Lee et al. established a direct interaction of the N-terminus of DAT
with the third intracellular loop of the D2 receptor (Lee et al., 2007). Given the fact that both
DAT and KOR are coexpressed in presynaptic DA-terminals (Svingos et al., 2001), and
KOR activation upregulates DAT surface levels, we postulated that DAT and KOR might
co-exist in a complex. To determine whether KOR and DAT formed interacting complexes
we used three approaches to investigate the DAT-KOR association: co-
immunoprecipitation, BRET and FRET in live cells to quantify the dynamics of DAT-KOR
association. First, co-immunoprecipitation experiments were carried out in cells
coexpressing myc-KOR and FLAG-DAT. Immunoprecipitation of myc-KOR with anti-myc
antibody followed by immunoblotting with anti-DAT antibody revealed a ∼ 85 kDa band
corresponding to mature, monomeric DAT in cells co-expressing both DAT and KOR
proteins (Fig. 6A lane 2). No specific DAT band was observed when Protein A beads were
used with non-transfected cellular extracts which indicates the specificity of the myc-
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antibody to the immunoprecipitated myc-KOR protein (Fig. 6A lane 3). Furthermore, no
specific DAT band was observed in the anti-myc-KOR immunocomplex isolated from the
mixture of lysates that were prepared from cells expressing myc-KOR alone or FLAG-DAT
alone (Fig. 6A lane 1). These results suggest that the formation of DAT-KOR complexes
requires the expression of DAT and KOR in the same cell and rules out a simply an artefact
due to solubilization and immunoprecipitation processes. Due to the presence of IgG in the
eluate from the immunocomplex and as a result of cross immunoreactivity with secondary
antibody, IgG bands were detected. In addition, to determine whether DAT/KOR complexes
also exist in native tissues, we blotted DAT immunoprecipitates from rat striatal
synaptosomes for KOR (Fig 6B). Immunoblotting of DAT immunoprecipitates (obtained
using two different DAT antibodies) with a polyclonal KOR antibody revealed the presence
of a ∼45 kDa band consistent with the expected size for KOR. In parallel experiments, the
∼45 kDa band is not immunoprecipitated from striatal extract when an irrelevant IgG (with
Protein A sepharose) is utilized for immunoprecipitations (Fig 6B). Second, we used BRET
(Angers et al., 2000) to determine whether DAT and KOR proteins are in close proximity
(<100.Å) to form interacting complexes (Fig. 6C & D). Co-expression of Luc-KOR and
DAT produced a positive energy transfer signal and an increased BRET ratio indicating that
Luc-KOR and DAT-YFP are in close proximity (<100 Å). In accord with previous studies,
an increased BRET ratio was observed in Luc-KOR and YFP-DOR expressing cells (Gomes
et al., 2003). No energy transfer occurred in cells co-expressing Luc-KOR and YFP-CCR5
(Fig. 6C & D); thus, validating our BRET experiments. Third, to further evaluate whether
DAT and KOR directly interact in living cells, we used FRET microscopy (Schmid and
Sitte, 2003) using the three-filter method according to Xia and Lou (2001) (Xia and Liu,
2001). Quantitative visualization of protein oligomerization in intact cells was achieved by
utilization of the IMAGE J imaging software (Feige et al., 2005) which allows to generate
nFRET images. We co-expressed CFP-DAT and YFP-KOR (C-DAT and Y-KOR,
respectively) and observed robust nFRET -signals (24.16 ± 1.7, n = 33; Fig. 7A & B): this
confirms the formation of C-DAT and Y-KOR oligomers in living cells. To signify our
FRET data, we also employed a membrane bound form of CFP that predominantly inserts
into the plasma membrane but expectedly does not physically interact with Y-KOR; co-
expression of a membrane attached CFP and Y-KOR yielded a nFRET value of 11.33 + 1.1
(n = 27; Fig. 7A & B), which was highly significant from the C-DAT/Y-KOR combination
(p < 0.001). Apparently, this membrane attached CFP can serve as a weak acceptor for YFP
fluorophores attached to proteins integral to membranes; indeed some spurious FRET signal
was visible upon co-expression with Y-KOR (Fig. 7A & B). Therefore, we sought to
determine if other membrane proteins interacted with Y-KOR similar to C-DAT. We
examined two CFP-labelled, closely related NSS-family members, namely the human
serotonin transporter (C-SERT) and the rat GABA transporter (C-GAT1; (Schmid et al.,
2001)). However, although these two transport proteins nicely expressed at the cell surface
(Fig. 7A) they only interacted spuriously with co-expressed Y-KOR at the extent of
membrane bound CFP (Fig. 7A & B). Importantly, a quantification of fluorescent images
included in this study showed no statistical significant difference in the expression levels of
Y-KOR or (F (3,110) =0.082; p = 0.97) or CFP-tagged transporters (C-DAT or C-GAT1 or C-
SERT) and membr.CFP (F (3,110) =0.053; p = 0.98) (Fig. 7C).
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3.5.2. Salvinorin A Enhances the Interaction of DAT and KOR—Two significant
results described so far led us to ask whether activation of KOR upon SalA binding could
increase the DAT-KOR association to trigger appropriate signals to regulate DAT activity:
(i) the effect of SalA on KOR-signaling that resulted in an increase in DAT activity and (ii)
the existence of DAT and KOR as a complex. To determine whether SalA influences the
existence of a DAT-KOR complex, the FRET analysis was conducted in HEK cells
coexpressing C-DAT and Y-KOR (Fig. 7A & B). nFRET-values increased significantly
after (1 min) the addition of 10 μM SalA and stayed constant up to 5 min (Fig. 8A & B) (p <
0.01, ANOVA with Tukey's multiple comparison test).
4. Discussion
Dopamine neurotransmission is regulated by modulation of dopamine release and DAT-
mediated uptake. SalA and synthetic KOR agonists decrease dopamine release in striatal
sub-regions. This action is thought to underlie the dysphoric and pro-depressant like effects
of these drugs. In addition, KOR agonists attenuate cocaine self-administration in rats and
reinstatement of cocaine seeking produced by experimenter-administered cocaine (Morani et
al., 2009; Schenk et al., 1999). They produce pro-depressant like effects in rodent models
(Todtenkopf et al., 2004). These effects have been linked to agonist-induced decreases in
dopamine release in brain regions subserving mood and motivation and subsequent changes
in dopamine transmission. Thus, the KOR system exerts an inhibitory control on DA release
in ventral striatum (Chefer et al., 2005; Heijna et al., 1990; Spanagel et al., 1992) and mPFC
cortex (Tejeda et al., 2013). Recent studies have demonstrated that, in mice, specific
deletion of KOR in dopaminergic neurons leads to anxiolytic-like effect on behaviour,
enhanced cocaine induced plasticity and disrupts development of KOR-mediated conditional
place aversion (Chefer et al., 2013; Tejeda et al., 2013; Van't Veer et al., 2013). More
significantly while KOR agonist U69,593 decreased DA overflow in nucleus accumbens and
prefrontal cortex in wild type mice, KOR agonist U69,593 had no effect in mice expressing
DA neurons with out KOR (Chefer et al., 2013; Tejeda et al., 2013). Although, these
findings signify an important role for the KOR in DA neurons in the regulation of
dopaminergic neurotransmission and KOR-mediated behaviours, DAT functional expression
and regulation need to be investigated. The present studies, prompted by the demonstration
that KOR and DAT are apposed in dopamine axonal varicosities (Svingos et al., 2001),
demonstrate that SalA rapidly increases DAT function both in heterologous cells and striatal
tissue through activating KOR and ERK1/2. Furthermore, we provide evidence for the
presence of physical association of DAT with KOR and that association DAT and KOR
enhanced upon SalA exposure.
4.1. SalA and other KOR agonists alter biogenic amine transporters function differentially
via a BNI–reversible mechanism
Quantification of ASP+ accumulation in cells transfected with KOR and DAT revealed a
rapid increase in DAT function following SalA exposure. Pretreatment with the selective
KOR antagonist, BNI, prevented the effect of SalA indicating that upregulation of DAT
function is KOR mediated. Other KOR agonists also upregulated DAT function that is
sensitive to BNI and thus, general activation of KOR appears to support DAT regulation. It
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has been shown that SalA exhibits stimulatory effect on dopamine D2 receptors (Beerepoot
et al., 2008; Seeman et al., 2009). Since both heterologously expressed D2R and
endogenously expressed D2R regulate DAT activity (Bolan et al., 2007; Lee et al., 2007;
Mayfield and Zahniser, 2001; Zapata et al., 2007); (Bowton et al.), it raises the question
whether D2R activation is involved in SalA mediated DAT upregulation. However, D2R
antagonist L-741,626 (Bowery et al., 1996) did not affect SalA induced increase in DAT
activity. In addition, SalA induced DAT activation is observed only in cells coexpressing
both DAT and KOR, but not in cells expressing DAT alone. These results confirm the
involvement of KOR, but not D2R in SalA induced stimulation of DAT activity.
Interestingly, SalA exhibits differential influence on amine transporters in that it increases
DAT function and decreases SERT function while having no effect on NET function. A
recent study demonstrated that U50,488 induced upregulation of SERT activity and surface
expression require p38α MAPK in serotonergic neurons in vivo and implicated to stress-
linked neuronal events (Bruchas et al., 2011). Thus this differential regulation of aminergic
neurotransmission by SalA may have consequences on KOR-linked behavioural out put. It is
also possible that differential regulation of aminergic neurotransmission may vary among
KOR agonists as well as to different environment.
4.2. SalA upregulates DAT function in PTX sensitive and ERK1/2-dependent mechanism
The finding that PTX prevented SalA-evoked increases in ASP+ accumulation indicates that
upregulation is Gi/Go-dependent. KOR activation induces ERK1/2 phosphorylation
(Belcheva et al., 2005; Bohn et al., 2000; Bruchas et al., 2008; Potter et al., 2011) for
reviews, see (Bruchas and Chavkin, 2010) and ERK1/2 modulates DAT function and cell
surface expression (Moron et al., 2003). Immunoblotting confirmed that SalA induces pERK
in EM4 cells coexpressing KOR and DAT. Furthermore, inhibition of this kinase prevented
SalA evoked upregulation of DAT function. The concentration of PD98059 used was lower
than that which inhibits DAT function (Moron et al., 2003). Therefore, the attenuated
response to SalA cannot be attributed to effects of the inhibitor alone. These data provide the
first demonstration that KOR regulates DAT via an ERK1/2-dependent mechanism. KOR is
also coupled to p38 MAPK activation demonstrated in vivo (Bruchas et al., 2011; Lemos et
al., 2012). However treatment of SalA, U69,593 or U50,488 for 5 min did not increase
phospho-p38 MAPK immunoreactivity. Consistently, inhibition of p38 MAPK failed to
modify the effect of SalA indicating a specific role for the ERK1/2 cascade in mediating the
functional modulation of DAT by this KOR agonist. In addition, Moron et al reported that
p38 MAPK inhibitor, SB 203580 failed to affect DAT activity in rat striatal synaptosomes
(Moron et al., 2003). It has been known that the KOR-mediated intracellular signaling
cascades vary depending on the cell model used as well as the ligand, dose and duration of
treatment, reviewed in (Bruchas and Chavkin, 2010).
4. 3. KOR activation by SalA and U50,488 increases DA clearance in striatum and SalA-
mediated DAT upregulation is ERK1/2 dependent
Studies using rat striatum revealed a BNI-sensitive rapid increase in dopamine clearance
following acute SalA or U50,488 exposure. Analogous to cells, ERK1/2 inhibition
attenuated the increase in striatal DAT function produced by SalA. These findings are
noteworthy. They demonstrate that SalA increases DAT function in native tissue by an
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ERK1/2-dependent mechanism. Furthermore, they indicate that the functional interaction of
KOR and DAT observed in heterologous systems is not due to high levels or artificial co-
expression of these proteins. Moreover, ERK1/2 activation has been documented in the
nucleus accumbens of acute and repeated SalA administered rats (Potter et al., 2011).
Kinetic analysis revealed a marked increase in the Vmax of DA or ASP+ transport in EM4
cells coexpressing DAT/KOR and in striatal synaptosomes respectively. However, while
SalA did not alter Km for DA in striatal synaptosomes, SalA increased Km for ASP+ uptake
in EM4 cells coexpressing DAT/KOR. Such differences could reflect the specific nature of
regulatory mechanisms in different environments (native versus heterologous), or DAT and
KOR coexpression ratio or other unknown processes that could affect DAT kinetics
differently. It may simply reflect sampling bias inherent in the single-cell assay conditions
of ASP+ uptake (fluorescence microscopy versus radiometric techniques) or use of native
DAT substrates DA versus ASP+ to assay DAT activity. Therefore, it is possible that KOR
mediated DAT regulation may vary based on the environment as well as brain regions.
Acute systemic administration of synthetic KOR agonists increases dopamine transport ex-
vivo in ventral but not dorsal striatum (Thompson et al., 2000). Moreover, in-vivo
quantitative microdialysis revealed no effect of systemic administration or local perfusion of
SalA on dopamine uptake in dorsal striatum (Gehrke et al., 2008). However, data regarding
the effects of SalA on basal dopamine clearance in ventral striatum are lacking. In the
present study, RDE voltammetry was performed in mince preparations of the dorsal and
ventral striatum and therefore it is difficult to conclude whether SalA mediated increase in
DAT-activity occurs in both regions or region specific. In this context, we recently reported
that KOR agonist U69,593 does not modify DAT- or NET-mediated DA uptake in mPFC
synaptosomes and conditional deletion of KORs on DA neurons does not change DA uptake
in mPFC assessed with no-net-flux microdialysis (Tejeda et al., 2013). Alternatively, the
half-life of SalA is short, ranging from 8-36 min (Hooker et al., 2008; Schmidt et al., 2005).
Therefore, the longer sampling duration required for microdialysis (e.g. >30 min) relative to
that of voltammetry (sec) may underlie the observed lack of effect in dorsal striatum.
4.4. KOR activation enhances DAT cell surface expression
Changes in Vmax are often due to alterations in protein trafficking. Constitutive DAT
trafficking between the membrane and intracellular compartments has been reported (Loder
and Melikian, 2003). Changes in trafficking enable rapid regulation of dopamine
transmission. Surface biotinylation studies revealed the enhanced surface DAT availability
following SalA exposure in both cells and native tissue suggesting that SalA increase DAT
function, in part, by promoting redistribution of DAT to the cell surface. Consistent with the
blockade effect of ERK1/2 inhibition on SalA induced upregulation of DAT activity,
inhibition of ERK1/2 prevented SalA triggered increase in surface DAT. However, level of
SalA induced DAT surface enhancement is higher than uptake suggesting the involvement
of multiple stages of transporter trafficking and catalytic activation and or due to different
assays employed (uptake versus biotinylationimmunoblot). It is noteworthy that regulation
of PKG and p38 MAPK-dependent SERT regulation has been associated with enhancement
of surface SERT followed by catalytic activation (Zhu et al., 2004). We have demonstrated
that activation of D3-dopamine receptor regulates DAT trafficking at the level of DAT
endocytosis - exocytosis – recycling in a biphasic manner to regulate surface DAT
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expression and function (Zapata et al., 2007). Further research is needed to fully identify
additional cellular mechanisms involved in the regulation of SalA-KOR mediated DAT
upregulation.
4.5. DAT and KOR exists in a physical complex
Co-immunoprecipitation studies from transfected cells coexpressing KOR and DAT and
striatal tissue suggest that KOR and DAT exist in a physical complex. Furthermore, BRET
experiments revealed energy transfer between Luc-KOR and YFP-DAT suggesting that they
are in close proximity. Importantly, energy transfer can arise from random interactions
within the membrane when high expression levels and single acceptor/donor ratios are
employed (James et al., 2006). Furthermore, FRET studies confirmed the presence of a
physical complex of DAT with KOR in living cells. Taken together, these results
demonstrate that KOR and DAT are in sufficient proximity to interact, although an indirect
interaction cannot be excluded. Interestingly, SalA treatment enhanced DAT-KOR assembly
suggesting that activation of KOR promotes and/or regulate DAT-KOR assembling.
Recently it has been demonstrated that A3 adenosine receptor activation augments SERT-A3
adenosine receptor complex formation (Zhu et al., 2011). Activation of NK1R triggers NET
redistribution through raft-mediated translocation of NET-NK1R complexes and facilitates
recruitment of signaling molecules (Arapulisamy et al., 2013). It is also possible that DAT
activation/inhibition by DAT substrates and inhibitors respectively may regulate KOR-
mediated DAT regulation and physical association of DAT and KOR.
4.6. Concluding remarks
Phosphorylation of monoamine transporters is one cellular mechanism by which protein
kinases regulate amine uptake. DAT contains putative consensus sites for several protein
kinases including potential phosphorylation sites for ERK (Ser-13, Thr-53; Thr-595)
(Gorentla et al., 2009). Mutation of Thr-53 eliminates ERK triggered DAT phosphorylation
providing direct evidence that Thr-53 is a phosphorylation site for ERK (Gorentla et al.,
2009) and also has functional significance (Foster et al., 2012). These findings raise the
possibility that ERK activation by SalA may promote DAT phosphorylation and this action
may contribute to SalA-evoked DAT upregulation. Studies addressing this issue are
currently in progress. Taken together, the results of the present study, demonstrating that
SalA increases DAT function suggests that it may affect behaviour and dopamine
neurotransmission by two distinct mechanisms, inhibition of release (Ebner et al., 2010) and
ERK dependent upregulation of dopamine transport. Furthermore, the demonstration that
KOR and DAT are in close proximity in both cells and native tissue (Svingos et al., 2001)
provides a cellular basis by which SalA and synthetic KOR agonists (Thompson et al., 2000)
regulate basal DAT function.
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BRET Biolumiescence Resonance Energy Transfer
DAT Dopamine transporter
ERK1/2 Extracellular signal-regulated kinases ½
FRET Fluorescence Resonance Energy Transfer FRET
GPCR G-protein coupled receptor
KOR kappa Opioid receptor
SalA Salvinorin A
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• Salvinorin A produces psychotomimesis, dysphoria and prodepressant like
effects.
• Major determinant of aminergic signalling is the activity of amine transporters.
• We studied the effect of Salvinorin A on amine transporter function.
• Salvinorin A upregulates dopamine uptake and surface transporter via KOR-
ERK1/2.
• κ-opioid receptor and dopamine transporter exist in a physical complex.
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Fig. 1. SalA and other KOR agonists alter biogenic amine transporters function differentially via
a BNI–reversible mechanism
EM4 cells were transiently cotransfected with myc-KOR plus YFP-DAT or myc-KOR plus
hSERT or myc-KOR plus hNET. After 48 h, DAT, SERT and NET functions were
measured as accumulation of ASP+ over time as described under Materials and Methods. A.
Influence of SalA concentrations (1 – 10 μM) on ASP+ accumulation rate (AFU). *p< 0.05;
**p < 0.001, (SalA 3 μM: n=47 and 10 μM: n=37 respectively) compared with vehicle
control (One-Way ANOVA with Dunnett's multiple comparison test. B. Effect of DAT
blocker GBR12909 on DAT mediated ASP+ accumulation. GBR12909 (10 μM) blocked
DAT mediated ASP+ accumulation both in the presence and absence of SalA. ****p<
0.0001 (SalA: n=73) compared to corresponding Veh/Veh control (N=31). ˆˆp< 0.01
(GBR12909/Veh: n=160; GBR12909/SalA: n=118 and nontransfected cells: N=144)
compared with Veh/Veh or Veh/SalA. The GBR12909 insensitive background signals were
similar to those observed in nontransfected cells. C. Effect of D2 receptor antagonist
L-741,626 on SalA induced increase in ASP+ accumulation. L-741,626 (10 μM) did not alter
SalA induced increase in ASP+ accumulation in EM4 cells coexpressing DAT and KOR.
**** p< 0.0001 compared with L-741,626/Veh (N=181). SalA failed to increase DAT-
mediated ASP+ accumulation in EM4 cells expressing DAT only. ˆˆp< 0.01 (N=157)
compared with Veh/SalA (N=149) or L-741,626/SalA (N=181) in cells coexpressing both
DAT and KOR. ns, non significant, p=0.84, (Veh/SalA versus L-741,626/SalA). D. Effect of
KOR agonists SalA (10 μM), U69,593 (10 μM) and U50,488 (10 μM) on DAT function.
BNI (1 μM) prevents KOR evoked DAT upregulation. ***p< 0.001 (SalA: n=64; U69,593:
n=35 and U50,488: n=55) versus corresponding Veh/Veh control; $$$p< 0.001 (n=60)
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versus Veh/SalA; ###p< 0.001 (n=42) versus Veh/U69,593 and ˆˆp< 0.001 (n=44) versus
Veh/U50,488. E. Effect of SalA (10 μM, 10 min) on SERT and NET function. A between
cell design was utilized to determine the effect of SalA. Background uptake values were
corrected and normalized to SERT or NET expression levels. ***p< 0.001 (n=47);
significantly different from Veh/Veh control; ˆˆp< 0.01 (n=16) significant different
compared with Veh/SalA. Data are the mean ± S.E.M (One-Way ANOVA with Bonferroni
multiple comparison test).
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Fig. 2. SalA upregulates DAT function in PTX sensitive and ERK1/2-dependent mechanism
EM4 cells co-expressing myc-KOR and YFP-DAT were pre-incubated with PTX (100 ng/
ml-16-24 hr) or PD98059 (10 μM-15 min) or vehicle prior to SalA (0; 10 μM) addition.
ASP+ uptake or t-ERK1/2 and p-ERK1/2 or phospho-p38 MAPK and t-p38 MAPK levels
were determined as described under Materials and Methods. A. PTX pretreatment prevents
SalA - evoked DAT upregulation. *p< 0.01 (n=87); significantly different from Veh/Veh
control; ˆp< 0.01 (n=64) significant difference compared with Veh/SalA (One-Way
ANOVA with Bonferroni multiple comparison test). B. Representative immunoblot showing
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phospho-ERK1/2, total ERK1/2, phospho-p38 MAPK and total p38 MAPK levels in vehicle
or SalA or U69,593 or U50,488 treated cells. C. Pre-treatment of ERK1/2 inhibitor PD98059
but not p38 MAPK inhibitor SB203580 prevents SalA – induced DAT activity. ***p< 0.001
(n=89); significantly different from Veh/Veh control; ˆˆˆp< 0.001 (n=71) significant
difference compared with Veh/SalA. Data are the mean ± S.E.M (One-Way ANOVA with
Bonferroni multiple comparison test). D. Representative immunoblot showing phospho-
ERK1/2, total ERK1/2, phospho-p38 MAPK and total p38 MAPK levels in vehicle or SalA
or PD98059 or PD98059/SalA treated cells.
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Fig. 3. KOR activation by SalA and U50,488 increases DA clearance in striatum and SalA-
mediated DAT upregulation is ERK1/2 dependent
Minced slice preparations from rat striatum were exposed to appropriate vehicle(s) or SalA
or U50,488 and RDE voltammetry was performed to measure DA clearance as described
under Materials and Methods. GBR12909 (100 nM) was used to determine the specific
DAT mediated DA clearance in RDE experiments. DA uptake in the presence of GBR12909
was subtracted from the total clearance to yield specific DAT-mediated DA uptake. A. KOR
antagonist BNI blocked SalA (10 μM) or U50,488 (10 μM) induced DAT-mediated DA
clearance. Slices were pre-incubated with BNI (1 μM-5 min) prior to SalA or U50,488 (0; 10
μM) addition. Values (pmoles/s/g tissue) represent the mean ± SEM of three independent
experiments. *p< 0.05; **p< 0.01 compared with Veh/Veh control. #p< 0.05 compared with
Veh/SalA. ˆp< 0.05 compared with Veh/U50,488. (One-Way ANOVA with Bonferroni
multiple comparison test). B. ERK1/2 inhibitor PD98059 prevents SalA induced changes in
dopamine clearance. Minced slice preparations from rat striatum were exposed to vehicle or
PD98059 (10 μM) for 10 min prior to the addition of SalA (0; 10 μM). RDE voltammetry
was performed to measure DA clearance as described under Materials and Methods. Values
were expressed as percentage of uptake relative to the uptake observed in Veh/Veh treated
slices and represent the mean ± SEM of three independent experiments. *p< 0.01 significant
difference between Veh/Veh versus Veh/SalA; ˆp< 0.04 significant difference between Veh/
SalA and PD98059/SalA (One-Way ANOVA with Bonferroni multiple comparison test).
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Fig. 4. SalA increases DAT Vmax
DA uptake kinetic characteristics mediated by DAT in vehicle or SalA treated striatal
synaptosomes. Synaptosomes (50 μg) were preincubated with the vehicle or SalA (10 μM)
for 5 min at 37°C. After this treatment, uptake of DA was measured (5 min) over a range of
0.01 to 2 μM mixed with 50 nM nisoxetine (to block NET mediated DA uptake) and
radiolabelled [3H]DA as described under Materials and Methods. In parallel, nonspecific
uptake at each concentration of DA used (in the presence of 100 μM cocaine) was subtracted
from total uptake. Values are the averages from three independent experiments, and the
mean values ± SEM are given. Nonlinear curve fits of data for uptake used the generalized
Michaelis–Menten equation (Prism).
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Fig. 5. SalA increases DAT cell surface expression and is ERK1/2 dependent
EM4 cells coexpressing myc-KOR and YFP-DAT or rat striatal synaptosomes were pre-
treated with vehicle or PD98059 (10 μM) for 15 min prior to SalA (0; 10 μM, 5 min)
followed by biotinylation. Isolation of biotinylated proteins, detection and quantification of
DAT were performed as described under Materials and Methods. Western blots of DAT
from total lysates and avidin bead eluates from striatal synaptosomes (A) and EM4 cells
coexpressing KOR and DAT (B) are shown at the top. Quantified surface DAT band
densities are shown at the bottom. *** p<0.001 (N=9) significant changes in biotinylated
DAT band densities compared with Veh/Veh control (n=8) or Veh/PD98059 (N=4) or
PD98059/SalA (N=9) in EM4 cells and striatal synaptosomes (Veh/Veh control (n=11) or
Veh/PD98059 (N=3) or PD98059/SalA (N=3). ˆˆp<0.005 (Veh/Sal versus PD98509/SalA).
Data are the mean ± S.E.M (One-Way ANOVA with Bonferroni multiple comparison test).
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Fig. 6. Presence of DAT and KOR as an oligomerization complex
A. Co-immunoprecipitation of KOR and DAT from EM4 cells transfected with myc-KOR
or Flag-DAT. Lane 1: Lysates from EM4 cells individually expressing myc-KOR or Flag-
DAT were mixed; immunoprecipitated (IP) with an anti-myc antibody and immunobloted
(IB) using an anti-DAT antibody. Lane 2: Lysates from EM4 cells coexpressing myc-KOR
and Flag-DAT were immunoprecipitated and immunobloted as described in lane 1. Lane 3:
non-transfected cells. A representative blot of n=5 experiments is shown. IgG bands were
detected due to the presence of IgG in eluate from immunocomplex and due to the cross
immunoreactivity of secondary antibody. B. Co-immunoprecipitation of DAT from rat
striatal synaptosomes. The synaptosomes were solubilized and immunoprecipitated using
two different DAT antibodies. Parallel experiments using irrelevant IgG were performed to
validate the specificity of immunoprecipitation. Presence of KOR from DAT-
immunocomplex was determined by immunoblotting with KOR antibody as described under
Materials and Methods. The experiment shown was replicated with similar results and
representative immunoblot is shown. C. BRET: KOR and DAT are in close proximity. HEK
cells were transfected as described in Methods and subjected to BRET analysis. Light
emission spectra for the conditions are shown. D shows the BRET ratios determined from
light emission spectra. **p<0.01.
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Fig. 7. FRET Analysis of DAT and KOR oligomerization in Living Cells
FRET microscopy showed the presence of DAT and KOR oligomerization in DAT and
KOR coexpressing intact cells as described under Materials and Methods. A. HEK293 cells
were cotransfected with YFP-KOR and CFP-tagged other cDNAs as given in the figure. 48
h post transfections, epifluorescence microscopy was performed in live cells. Images from
the filter sets, CFP (first column), YFP (second column) and corrected and normalized
FRET (nFRET) images (third column) are shown. A color code used is also presented on the
right corner of the figure. Background fluorescence was subtracted from all images
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presented. B. Normalized FRET efficiencies are given from cells coexpressing CFP-DAT +
YFP-KOR (n=33); membr.CFP + YFP-KOR (n=27); CFP-GAT1 + YFP-KOR (n=27) and
CFP-hSERT + YFP-KOR (n=27). **Significant difference between CFP-DAT + YFP-KOR
and membr.CFP + YFP-KOR (p<0.0001) or CFP-DAT + YFP-KOR and CFP-GAT1 +
YFP-KOR (p<0.0001) or CFP-DAT + YFP-KOR and CFP-hSERT + YFP-KOR (p<0.0001).
C. Expression levels of CFP-DAT, Membr-CFP, CFP-GAT1, CFP-SERT and YFP-KOR.
Intensity of fluorescence was measured in a 1 pixel-broad rim positioned over the
membrane. Values were expressed as arbitrary fluorescence units (a.f.u.). Data were
analysed using One-way ANOVA with Bonferroni's multiple comparisons test.
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Fig. 8. SalA treatment increases DAT and KOR oligomerization
HEK293 cells coexpressing DAT-CFP + YFP-KOR were exposed to SalA (10 μM) for
various times (0 to 6 min) followed by FRET analysis as described in Fig. 6 and under
Materials and Methods. A. Images obtained at different time periods using different filter
sets, DAT-CFP (first row from the top), YFP-KOR (second row from the top) and corrected
and normalized FRET (nFRET) images (third row from the top) and the color code are
shown. B. Normalized FRET efficiencies for each time points are given. **Significant
difference between 0 and 1 min (p<0.001, n= 4), 0 and 3 min (p<0.005, n= 4) and 0 and 5
min (p<0.008, n= 4). Data were analysed using One-way ANOVA with Bonferroni's
multiple comparisons test.
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